Bojmar Lab

PhD, Assistant Professor, Docent

Linda Bojmar. Photo credit John Karlsson Linda Bojmar did her graduate studies in Linköping Sweden, where she was born. Thereafter, Linda performed her postdoctoral studies in the lab of Dr. David Lyden at Weill Cornell Medicine, New York. Here, Linda studied extracellular vesicles and their role in cancer progression. Together with Memorial Sloan Kettering, Linda performed the first studies of the hepatic pre-metastatic niche in pancreatic cancer patients. These projects set the stage for Linda’s translational lab in Sweden, working on the systemic effects of cancer, and how to employ them to improve care, together with clinicians and pre-clinicians. Linda’s passion is to work in multi-disciplinary teams, and when not running between the hospital and the lab, Linda likes to spend her time outside, preferably with family, friends and horses!

Pathologist, PhD candidate

Hakon Andersen Blomstrand was born in Uppsala, Sweden. He graduated from medical school at University of Gothenburg in 2013. He is interested in all aspects of pancreatic cancer, an interest that started while working clinically with cancer patients. He is currently working and doing his doctoral training at the Department of Clinical Pathology at Linköping University Hospital. In his spare time, Hakon enjoys hiking and climbing.

PhD candidate

Elena Arlaman was born and raised in Syria. She spent three years studying pharmacy at Damascus University before relocating to Sweden in 2014. In Sweden, she studied medicine at Linköpings University and graduated with a master's degree in medicine in January 2023.

Elena's passion for research has been a driving force throughout her academic journey. She actively participated as a research assistant during her medical studies, working with a research group at Linköping University focused on studying thrombocytes and coagulation factors.

However, Elena's goal has always been to become an oncologist and cancer researcher. In April 2023, she embarked on a new academic adventure as a PhD candidate in cancer research under the supervision of Linda Bojmar. Her particular research interest lies in the study of cancer-derived extracellular vesicles and their role in cancer progression, as well as their potential utility as biomarkers.

PhD candidate

Photo credit Emma Busk Winquist Jonas Burman grew up in Karlstad but moved to Linköping for his bachelor’s studies in Biology. During this time, he discovered his growing interest in understanding how humans worked, rather than the study of animals and ecology and went on to pursue a master’s degree in Experimental and Medical Biosciences at the university hospital in Linköping, graduating in 2022. For his master’s thesis, he focused on the role of the putative tumor suppressor TAp73 in radiosensitivity under the supervision of Xiao-Feng Sun. After his master’s degree he decided to dive further into the topic of enhancing treatment of colorectal cancer by enrolling in graduate studies under Linda Bojmar as a PhD candidate.

He is interested in molecular factors which differentiate patients that respond well to radiotherapy to those that do not, and the mechanisms behind this, using bioinformatics and wet-lab assays. Already during his master’s degree, the small molecule APR-246, or Eprenetapopt, which appears to have cause cell death in cells with mutant p53, but also could be useful in improving response rate to conventional treatment piqued his interest. Recently, the topic that has been of interest is the study of the potential of cargo from extracellular vesicles shed from the primary tumor, to alter the tumor microenvironment, establishing a pre-metastatic niche in distant tissues, as well as how this relates to treatment response in colon and rectal cancer.

MD, PhD, Docent / Senior consultant

The research Bergthor Björnsson conduct is largely based on collaborations in various networks. After his defense in 2014, he ran a randomized trial at US (Linköping) where the value of minimally invasive pancreatic surgery was evaluated. At the same time, his unit led a multicenter and multinational study comparing different liver surgeries. It became clear that to tackle the larger clinical issues, large networks are needed. Therefore, he participate in the research for clinical projects described on his employee page.

Translational research often requires closer collaboration than clinical research and there can be difficulties with large distances. Therefore, the translational part of his research is mainly conducted in collaboration with other researchers at Linköping University.

Research Engineer

Carolin Jönsson. Carolin Jönsson grew up in the South of Germany and graduated as a research technician at the Max-Planck Institute in Freiburg, Germany.

She then worked at Friedrich Miescher Institute in Basel Switzerland and The Hospital for Sick Children in Toronto Canada.

She moved 1993 to Sweden and worked at Uppsala University and Lund University until she finally came to Linköping University in 2003.

Throughout the years Carolin has worked in many different research fields.

She joined the Bojmar group in 2022. Carolin is responsible for collecting and “processing” all patient material and is involved in different projects concerning the understanding of the pre-metastatic niche in pancreatic cancer and the role of extracellular vesicles as a biomarker for metastasis.

In her spare time she enjoys kayaking, gardening and arts.

MD, Surgical consultant, PhD candidate

Erik Lundqvist is a local ability, born in a small town called Söderköping in Östergötland county. After medicine degree in Linköping University and internship at Vrinnevi hospital, Norrköping, he started his career as a surgical resident in the department of Surgery, Vrinnevi hospital. The scientific career started with an observation study of hereditary evaluation of young persons diagnosed with colorectal cancer in the South-East Healthcare region. He is now a surgical consultant and PhD-student at Linköping University, with main focus on risk factors and outcome in young individuals with colorectal cancer. The collaboration with Linda Bojmar started in 2022 and sampling of colon cancer patients treated with surgery in Norrköping started in 2023.

The overall aim with his research is to improve the diagnosis and management of patients with colorectal cancer, a disease affecting almost 7000 new individuals in Sweden each year.

MD

Paulina Velasco Riestra. Paulina Velasco Riestra graduated as an MD from Tecnológico de Monterrey University in Mexico City. She began her career as a researcher at MD Anderson, delving into mucin secretion within the Pulmonary Medicine division. Motivated by a profound interest in pediatric oncology, she transitioned to clinical training, discovering her passion for both the clinical and research facets of the field. Under the guidance of Dr. Sebastián Rodríguez Llamazares, she contributed to establishing the pleural clinic at the Mexican National Institute of Respiratory Diseases.

Currently, Paulina collaborates in Linda Bojmar's research group, focusing on cancer-derived extracellular vesicles. She cherishes moments with friends and family, finding joy in baking. Her commitment to both professional and personal spheres underscores her lagom approach to life.

MD, MRes

Constantinos Zambirinis. Constantinos Zambirinis, is a surgeon-scientist, originally from Paphos, Cyprus. He graduated from the University of Athens Medical School in Greece, and completed a Masters of Research in Translational Cancer Medicine at King's College London, UK. He spent 12 years in the U.S. during which he completed clinical training in General Surgery (Harlem Hospital Center, NY, and Rhode Island Hospital of Brown University, RI) and Complex General Surgical Oncology (Rutgers Cancer Institute of New Jersey). He also spent several years in the lab, first at New York University and subsequently at Memorial Sloan Kettering Cancer Center, studying the role of inflammation in pancreatic carcinogenesis as well as the liver pre-metastatic niche.

His research focuses on immune-mediated mechanisms of pancreatic cancer progression and metastasis, and the development of novel approaches for radiomic and molecular profiling of pancreatic cancer in order to predict outcomes and tailor treatment to each patient's individual tumor.